Evidence map›Paper›PMID 35562592›Full record

ArticleThe Journal of antibiotics2022

In vitro activity of ceragenins against Burkholderia cepacia complex.

Elif Sena Demir, Ozlem Oyardi, Paul B Savage, Havva Ozlem Altay, Cagla Bozkurt-Guzel

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 65% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Enhancing the destruction ofFrontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Elif Sena DemirIstanbul University, Institute of Graduate Studies in Health Sciences, 34116, Istanbul, Turkey. elifsenademir@gmail.com.
Ozlem OyardiDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, 34116, Istanbul, Turkey.
Paul B SavageDepartment of Chemistry and Biochemistry, Brigham Young University, 84602, Provo, UT, USA.
Havva Ozlem AltayScience for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, 17121, Sweden.
Cagla Bozkurt-GuzelDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, 34116, Istanbul, Turkey.
Istanbul University · TRBrigham Young University · USKTH Royal Institute of Technology · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Burkholderia cepacia complex (Bcc) species are aerobic, Gram-negative and non-fermantative bacilli. Bcc can cause clinical symptoms in patients with cystic fibrosis, ranging from asymptomatic carriage to fatal pneumonia. A pressing need exists for new antimicrobial agents that target Bcc. Ceragenins, CSA-13, CSA-131 and CSA-131 with 5% Pluronic® F127 (CSA-131P), were evaluated against Bcc clinical isolates (n = 42). MICs of ceragenins and conventional antibiotics were determined. Time-kill curve experiments were performed with 1x, 4x MICs of ceragenins and sulfamethoxazole-trimethoprim (SXT), levofloxacin. MIC

Indexed as

Burkholderia cepacia complexAnti-Bacterial AgentsHumansLevofloxacinMicrobial Sensitivity TestsSteroidsAnti-Bacterial AgentscerageninsLevofloxacinSteroids

Identifiers

PMID35562592
OpenAlexW4280568699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.